Limited data about use of biosimilars are available in children with Juvenile Idiopathic Arthritis (JIA). This study therefore aimed to evaluate long-term efficacy and safety of switching from etanercept (ETA) and adalimumab (ADA) originators to their biosimilars, in children with JIA, in a real-world setting.
OBSIDIAn - real world evidence of Originator to BioSImilar Drug switch in juvenile idiopathic arthritis / Maccora, Ilaria; Lombardi, Niccolò; Crescioli, Giada; Bettiol, Alessandra; Bonaiuti, Roberto; Pagnini, Ilaria; Maniscalco, Valerio; Marrani, Edoardo; Mastrolia, Maria Vincenza; Ravaldi, Claudia; Consolini, Rita; Cattalini, Marco; Vannacci, Alfredo; Simonini, Gabriele. - In: RHEUMATOLOGY. - ISSN 1462-0324. - STAMPA. - (2022), pp. 1518-1528. [10.1093/rheumatology/keab572]
OBSIDIAn - real world evidence of Originator to BioSImilar Drug switch in juvenile idiopathic arthritis
Maccora, Ilaria;Lombardi, Niccolò;Crescioli, Giada;Bettiol, Alessandra;Bonaiuti, Roberto;Pagnini, Ilaria;Marrani, Edoardo;Ravaldi, Claudia;Vannacci, Alfredo;Simonini, GabrieleSupervision
2022
Abstract
Limited data about use of biosimilars are available in children with Juvenile Idiopathic Arthritis (JIA). This study therefore aimed to evaluate long-term efficacy and safety of switching from etanercept (ETA) and adalimumab (ADA) originators to their biosimilars, in children with JIA, in a real-world setting.
| File | Dimensione | Formato | |
|---|---|---|---|
|
keab572.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
301.15 kB
Formato
Adobe PDF
|
301.15 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
